Patient reps on FDA panels and pharma funding: what do clinicians think?

A new study reports that patient and consumer representatives who take part in FDA advisory panels are often connected to organizations that receive money from the pharmaceutical industry. This raises questions about transparency and conflicts of interest in how drugs are evaluated. The source description does not make clear the scale of the work or its methodology, so it is worth checking the conclusions against the original paper. What shall we discuss: — How much can pharma funding of a patient organization shape its representative's position on a panel, and how could that be assessed? — Which transparency measures would be reasonable: disclosure of funding sources, limits on participation, or something else? — How do you explain to patients and colleagues that the patient voice in regulatory decisions is valuable but must be independent? The topic connects to the USMLE ethics and professionalism content: conflicts of interest, transparency of regulatory decisions, and the FDA's role in drug approval. Full article: drasiiavinograd.com/blog/fda-advisory-committee-conflict-of-interest-u Source: Medical Xpress medicalxpress.com/news/2026-10-fda-patient-consumer-reps-pharma.html